IXC – Invex Therapeutics Limited
Invex Therapeutics is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury.
The Company intends to achieve this through the research, development and potential commercialisation of more than 10 years of scientific discovery and technology development by Dr Alexandra J Sinclair and her group at The University of Birmingham, UK.
It is anticipated that IXC will list on the ASX during July 2019.
